Hungarian intelligence agency interviewed CEO linked to exploding Hezbollah pagers
Son of Uganda's president ends 2026 election bid
Trump to visit North Carolina as scandal swirls around Republican ally
EU member Cyprus calls on Lebanon, Israel to show restraint in Middle East
Iran's Supreme Leader says Israel is committing 'shameless crimes' against children
US election uncertainty clouds UN climate finance progress
Seal marks her 50th birthday at a sanctuary. Sheba may be the oldest in captivity
SAIC Volkswagen says adjusting plant base "necessary"
Oktoberfest is open. The world’s largest folk festival begins after ceremonial keg-tapping
Low brow and vulgar? Micro dramas shake up China's film industry, aim for Hollywood
The Midwest could offer fall’s most electric foliage but leaf peepers elsewhere won’t miss out
(Reuters) - Bristol-Myers Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings.
The U.S. initial public offering market is in the early innings of a recovery on hopes of potential interest-rate cuts and lower market volatility.
Zenas BioPharma, an immunology and inflammation focused biopharma company, said it has raised $358.3 million from investors since its inception.
The company's investors include Tellus BioVentures, Fairmount, Norwest Venture Partners, Enavate Sciences and Bristol-Myers Squibb.
The firm's losses widened to $65.8 million for the six months ended June 30, compared with $48.1 million, a year earlier. It did not reveal the number of shares it planned to sell and the proposed price range.
The company expects its shares to trade on the Nasdaq Global Market under the ticker symbol 'ZBIO'. Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities are the underwriters.
(Reporting by Manya Saini in Bengaluru; Editing by Arun Koyyur)
